APOE4 carriers: Your brain's immune system may already be compromised

Chimera experiments transplanting human APOE4 microglia into mice show these cells move chaotically, respond poorly to injury, and leave debris behind. APOE4 microglia are stuck in overdrive while failing at cleanup duties, acting like security guards who panic at everything but miss actual threats. Critically, these dysfunctions appear early in life rather than emerging in old age, meaning APOE4 carriers have an altered brain immune system throughout their lifespan.

CHCHD2 is a gene critical for mitochondrial energy production. Research presented at AAIC 2025 showed CHCHD2 completely disappears in APOE4 microglia, meaning the brain immune cells are literally running on fumes even when carriers feel mentally sharp. This early mitochondrial shutdown helps explain why APOE4 microglia fail at their energy-intensive cleanup jobs, and points to mitochondrial support as a potential intervention target for carriers.

Fibronectin is a sticky matrix protein that APOE4 causes blood vessel support cells to overproduce. It acts like molecular velcro, trapping amyloid near vessel walls. This helps explain why some Alzheimer antibody treatments cause dangerous bleeding (ARIA) in APOE4 carriers. Remarkably, some APOE4 homozygotes who stay sharp into their 90s carry natural fibronectin mutations, suggesting the fibronectin pathway is a promising therapeutic target.

Early research suggests yes. Blocking TGF-beta reversed blood vessel damage in experimental models: pericytes returned to their posts, fibronectin decreased, and the blood-brain barrier began healing. This is more than slowing decline, it is cellular reprogramming. Combined with vitamin D optimization, microglia-targeted lifestyle interventions, and inflammation tracking, the data suggests APOE4 carriers have meaningful room to bend the trajectory even after damage has begun.

APOE2 carriers (the protected genotype) have enhanced vitamin D receptor signaling and IL-10 anti-inflammatory pathways built in. APOE4 carriers lack these built-in brakes. If you also have darker skin or live far from the equator, vitamin D synthesis is further reduced, creating a double hit that can accelerate risk. Optimizing vitamin D status through testing, sunlight, and supplementation is a simple, actionable lever specifically relevant to APOE4 carriers.